Ask AI

HOPA 2026

 
Join Us for New Exciting Webinars Every Month
ACPE logo

Free Pharmacy Credit & More!

Multiple dates and times are being offered for these dynamic, pharmacy‑focused educational sessions designed to keep you at the forefront of oncology practice. Whether you’re interested in subcutaneous multitumor IO, NDMM, HR-positive/HER2‑negative AE management, myeloma therapeutics, HR-positive/HER2‑negative EBC, or bispecific antibodies in myeloma, these expert‑led programs offer timely insights you can put into practice right away.

Every session is free, accredited, and tailored to support the evolving needs of oncology pharmacists—so pick the topics that matter most to you and elevate your expertise.

 

Dates Thursday, April 30, 2026
Thursday, May 07, 2026
Wednesday, May 13, 2026
Thursday, May 14, 2026
Tuesday, May 19, 2026
Wednesday, May 20, 2026
Wednesday, May 27, 2026
Thursday, May 28, 2026
Monday, June 15, 2026

 

Time Varies per Event
Timezone Converter ›

Event Schedule

Featured Faculty

Faculty

James A. Davis, PharmD, BCOP

  • Clinical Pharmacy Specialist, Myeloma/Lymphoma
  • The Medical University of South Carolina, Hollings Cancer Center
  • Affiliate Assistant Professor
  • MUSC College of Pharmacy
  • Charleston, South Carolina
Faculty

Nina DiPierro, PharmD, BCOP

  • Clinical Oncology Pharmacist
  • ACCP Precision Medicine: Oncology Genomics Certified
  • Florida Cancer Specialists and Research Institute
  • Fort Myers, Florida
Faculty

Jordan Hill, PharmD, BCOP

  • Clinical Pharmacy Specialist, Breast Oncology
  • West Virginia University Cancer Institute
  • Morgantown, West Virginia
Faculty

Rodney Hunter, PharmD, BCOP

  • Director of Clinical Services
  • Memorial Hermann Texas Medical Center
  • Clinical Pharmacy Specialist
  • University of Texas Health Memorial Hermann Cancer Center
  • Professor
  • Texas Southern University College of Pharmacy and Health Sciences
  • Clinical Adjunct Professor
  • McGovern Medical School
  • Houston, Texas
Faculty

Kelley L. Julian, PharmD, BCOP

  • Hematology/BMT Pharmacy Supervisor
  • PGY2 Oncology Pharmacy Residency Program Director
  • Huntsman Cancer Institute, University of Utah
  • Salt Lake City, Utah
Faculty

Shawna Kraft, PharmD, BCOP

  • Clinical Pharmacist Specialist, Oncology
  • Michigan Medicine, University of Michigan
  • Clinical Associate Professor/University of Michigan College of Pharmacy
  • Ann Arbor, Michigan
Faculty

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP

  • Clinical Oncology Pharmacy Manager
  • Atrium Health Levine Cancer Institute
  • Charlotte, North Carolina
Faculty

Anthony J. Perissinotti, PharmD, BCOP

  • Hematology Clinical Pharmacist Specialist
  • University of Michigan
  • Ann Arbor, Michigan
Faculty

Danielle Roman, PharmD, BCOP

  • Manager, Oncology Clinical Pharmacy Services
  • Oncology Clinical Pharmacy Specialist
  • Allegheny Health Network
  • Pittsburgh, Pennsylvania
Faculty

Kelly Romo, PharmD, BCOP

  • Manager, Oncology Medical Drug Management and Customer Initiatives
  • Blue Cross Blue Shield of Michigan
  • Ann Arbor, Michigan
Faculty

Sara A. Scott, PharmD, BCOP

  • Clinical Pharmacy Specialist, Multiple Myeloma
  • Emory Winship Cancer Institute
  • Atlanta, Georgia
Faculty

Katie (Katelyn) Toeniskoetter, PharmD, BCOP

  • Disease-Group Research Pharmacist, Thoracic
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts
Faculty

Julia L. Ziegengeist, PharmD, BCOP

  • Clinical Pharmacist Specialist, Breast Medical Oncology
  • Levine Cancer, Atrium Health
  • Charlotte, North Carolina

Accreditation

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-164-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-002-L01-P has been assigned to this live application-based activity (initial release date 4/30/2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-003-L01-P has been assigned to this live application-based activity (initial release date May 13, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Advancing Pharmacist Excellence in Solid Tumors: Essential Considerations for Expanding From IV to Subcutaneous ICIs

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-004-L01-P has been assigned to this live application-based activity (initial release date May 14, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-005-L01-P has been assigned to this live application-based activity (initial release date May 19, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-006-L01-P has been assigned to this live application-based activity (initial release date May 20, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Staying the Course: Pharmacist Best Practices for Managing Adverse Events and Maintaining Therapy in EGFR-Mutated NSCLC

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-007-L01-P has been assigned to this live application-based activity (initial release date May 28, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgements

An independent, commercially supported symposium held in conjunction with the HOPA 2026 Annual Conference.

Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by an educational grant from Lilly.

Targeting BCMA in Early Relapsed/Refractory Myeloma: What Oncology Pharmacists Need to Know Now and in the Near Future
Provided by ProCE, LLC
Supported by an educational grant from GSK.

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists
Provided by ProCE, LLC
Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Advancing Pharmacist Excellence in Solid Tumors: Essential Considerations for Expanding From IV to Subcutaneous ICIs
Provided by ProCE, LLC
Supported by an educational grant from Merck Sharp & Dohme LLC.

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists
Provided by ProCE, LLC
Supported by an educational grant from AstraZeneca.

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care
Provided by ProCE, LLC
Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Staying the Course: Pharmacist Best Practices for Managing Adverse Events and Maintaining Therapy in EGFR-Mutated NSCLC
Provided by ProCE, LLC
Supported by an educational grant from Johnson & Johnson.

Mailing Address
Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

For customer support please email:
customersupport@deceraclinical.com